Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat liver disease and cancer, announced that Erin Quirk, M.D., Chief Medical Officer, will present a corporate overview and update on the Company’s lead clinical programs at the Jefferies Virtual Healthcare Conference taking place June 2-4, 2020.
FOSTER CITY, Calif. & SHANGHAI--(BUSINESS WIRE)-- Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat liver disease and cancer, today announced that Erin Quirk, M.D., Chief Medical Officer, will present a corporate overview and update on the Company’s lead clinical programs at the Jefferies Virtual Healthcare Conference taking place June 2-4, 2020. Terns will present at 4:30 pm ET (1:30 p.m. PT) on June 2.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is focused on the discovery and development of medicines for chronic liver disease and cancer. Based in China and the United States, the company is advancing a pipeline of drug candidates for the treatment of non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and cancer, across multiple modalities. Terns leverages world class expertise in disease biology, medicinal chemistry, and clinical development in order to bring promising new therapies to patients.
For more information, visit www.ternspharma.com and www.ternspharma.com.cn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200526005255/en/
US Media Contact:
Margaret Robinson
(415) 690-0084
China Media Contact:
Zhou Zhou
+86 13482103703
Source: Terns Pharmaceuticals, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20200526005255/en
